Haemoglobin transfusion threshold in traumatic brain injury optimisation (HEMOTION): a multicentre, randomised, clinical trial protocol

Alexis F Turgeon,1,2 Dean A Fergusson,3,4 Lucy Clayton,1,5 Marie-Pier Patton,1 Ryan Zarychanski,6,7 Shane English,3,4,8 Annemarie Docherty,9 Timothy Walsh,9 Donald Griesdale,10,11,12 Andreas H Kramer,13 Damon Scales,14,15 Karen E. A. Burns,14,16 John Gordon Boyd,17,18 John C Marshall,14,16,19 Demetrios J Kutsogiannis,20 Ian Ball,21,22 Paul C Hébert,23 Francois Lamontagne,24,25 Olivier Costerousse,1 Maude St-Pierre,26 Paule Lessard Bonaventure,1,27 Lynne Moore,1,28 Xavier Neveu,1 Andrea Rigamonti,14,29 Kosar Khwaja,30 Robert S Green,31,32 Vincent Laroche,1,33 Alison Fox-Robichaud,1,34 Francois Lauzier,1,2,33 for the HEMOTION Trial Team, the Canadian Critical Care Trials Group, the Canadian Perioperative Anesthesia Clinical Trials Group and the Canadian Traumatic Brain Injury Research Consortium

ABSTRACT

Introduction Traumatic brain injury (TBI) is the leading cause of mortality and long-term disability in young adults. Despite the high prevalence of anaemia and red blood cell transfusion in patients with TBI, the optimal haemoglobin (Hb) transfusion threshold is unknown. We undertook a randomised trial to evaluate whether a liberal transfusion strategy improves clinical outcomes compared with a restrictive strategy.

Methods and analysis HEMOGlobin Transfusion Threshold in Traumatic Brain Injury OptimizAtion (HEMOTION) is an international pragmatic randomised open label blinded-endpoint clinical trial. We will include 742 adult patients admitted to an intensive care unit (ICU) with an acute moderate or severe blunt TBI (Glasgow Coma Scale ≤12) and a Hb level ≤100 g/L. Patients are randomly allocated using a 1:1 ratio, stratified by site, to a liberal (triggered by Hb ≤100 g/L) or a restrictive (triggered by Hb ≤70 g/L) transfusion strategy applied from the time of randomisation to the decision to withdraw life-sustaining therapies, ICU discharge or death. Primary and secondary outcomes are assessed centrally by trained research personnel blinded to the intervention. The primary outcome is the Glasgow Outcome Scale extended at 6 months. Secondary outcomes include overall functional independence measure, overall quality of life (EuroQol 5-Dimension 5-Level; EQ-5D-5L), TBI-specific quality of life (Quality of Life after Brain Injury; QOLIBRI), depression (Patient Health Questionnaire; PHQ-9) and mortality.

Ethics and dissemination This trial is approved by the CHU de Québec—Université Laval research ethics board (MP-20-2018-3706) and ethic boards at all participating sites. Our results will be published and shared with relevant organisations and healthcare professionals.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The multicentre international recruitment and our pragmatic approach will provide generalisable findings.
⇒ The blinded outcome assessment will minimise ascertainment bias.
⇒ The sample size and sliding dichotomy analysis will increase our ability to detect smaller effect size with similar power for a given population size.
⇒ Transfusions administered as part of the initial resuscitation of acute trauma prior to intensive care unit admission will not be protocolised.

Trial registration number NCT03260478.

INTRODUCTION

Traumatic brain injury (TBI) is a significant public health concern and represents the leading cause of mortality and long-term disability in young adults.1 For these patients, the cerebral autoregulation that normally compensates for variations in oxygen delivery is impaired, rendering their brain vulnerable to ischaemia and secondary injuries. In the absence of high-quality evidence, several experts have suggested maintaining higher haemoglobin (Hb) levels (>100 g/L) on the assumption that it reduces metabolic distress and improves brain tissue oxygenation.3-5

The adoption of a liberal transfusion strategy...
has important resource implications since most patients with TBI will develop anemia and approximately one-third will be transfused during their hospital stay.

The evidence to support transfusion strategies in patients with TBI remains scarce. In a systematic review of studies in neurocritical care patients, we found insufficient evidence to support the use of a specific transfusion threshold to improve morbidity and mortality. A recent randomised controlled trial showed no effect of red blood cell (RBC) transfusion on neurological outcomes in patients with moderate or severe TBI, although the expected effect size was large and most patients included were not anaemic. To date, clinical practice guidelines are based on limited evidence and do not provide clear recommendations regarding RBC transfusion in TBI. As a result, transfusion practices vary greatly within and between centres; many clinicians extrapolate the evidence supporting the non-inferiority of a restrictive strategy in critically ill patients without TBI while others advocate for a liberal transfusion strategy pending stronger evidence to support this practice.

In collaboration with the Canadian Critical Care Trials Group (CCCTG), the Perioperative Anesthesia Clinical Trials Group and the Canadian Traumatic Brain Injury Research Consortium (CTR), we designed the HEMoglobin Transfusion Threshold in Traumatic Brain Injury OptimizatiOn (HEMOTION) trial. The primary objective of our international pragmatic randomised open label blinded-endpoint trial is to evaluate whether a liberal (higher Hb threshold) versus a restrictive (lower Hb threshold) RBC transfusion strategy improves neurological outcomes in anaemic moderate and severe TBI patients admitted to the intensive care unit (ICU). Secondary objectives will evaluate the effect of transfusion strategies on functional outcome, quality of life, depression and mortality. Tertiary objectives will evaluate the effect of transfusion strategies on the incidence of transfusion-related complications, infections, Hb levels, number of RBC units transfused and ICU and hospital length of stay. Herein, we report the trial protocol according to the SPIRIT statement. This trial is registered with ClinicalTrials.gov.

**METHODS AND ANALYSIS**

**Trial settings and eligibility criteria**

The HEMOTION trial is being conducted in level 1 and level II trauma centres in Canada, the United Kingdom, Brazil and France since September 2017. We are recruiting adult patients (≥18 years old) admitted to the ICU with an acute (hospital admission within 24 hours of injury) moderate or severe (Glasgow Coma Score (GCS) ≤12) blunt TBI and a Hb level ≤100 g/L. We exclude patients who receive transfusion after ICU admission, have contraindications or known objection to transfusions or have no fixed address. We also exclude patients who meet the criteria for neurological determination of death, those with a GCS of 3 in combination with bilateral fixed dilated pupils, those with active life-threatening bleeding associated with haemorrhagic shock, and patients for whom a decision to withhold or withdraw life-sustaining therapies has been made at the time of screening. Patients who received transfusion prior to ICU admission (eg, in the emergency room or in the operating room), as part of the initial acute trauma resuscitation, are eligible. Research coordinators at each participating site screens daily all critically ill adult patients with TBI to determine eligibility. Table 1 depicts the schedule of interventions, data collection and outcome assessments. In the final report, we will report excluded patients and reasons for non-enrolment using the Consolidated Standards of Reporting Trials flow diagram (figure 1).

**Assignment of interventions**

On reaching a Hb ≤100 g/L and after a site investigator confirms eligibility, the research coordinator uses a secure, web-based, central, concealed, computerised randomisation portal to allocate patients in a 1:1 ratio to either a liberal (experimental) or a restrictive (control) RBC transfusion strategy. Randomisation is done with variable permuted blocks of 4 and 6, stratified by site. Staff members of the methods centre of the Ottawa Health Research Institute (OHRI) who are not involved in trial implementation generated the randomisation sequence.

**Interventions**

Once randomised, the trial intervention is initiated within 3 hours in patients meeting the threshold for transfusion in their respective group to avoid prolonged exposure to Hb levels below this threshold.

**Experimental intervention: liberal transfusion strategy**

Patients in the liberal transfusion strategy group receive an RBC transfusion if their Hb is ≤100 g/L. This threshold, shown to be effective in maintaining adequate cerebral oxygenation, is considered acceptable by clinicians caring for critical care patients with neurological injuries.

**Control intervention: restrictive transfusion strategy**

Patients in the restrictive transfusion strategy group receive an RBC transfusion only if their Hb is ≤70 g/L. We have chosen this threshold because it is the most studied restrictive RBC transfusion threshold and reflects the current standard of care in non-bleeding critically ill patients without neurological or coronary artery diseases. It also is a frequently used and accepted threshold for clinicians who care for brain-injured patients.

**Duration of treatment**

The allocated transfusion strategy is applied throughout the ICU stay until ICU discharge, death or a decision to withdraw life-sustaining therapy is made, whichever comes first. The study procedures are also implemented in the operating room, provided the patient is still admitted to the ICU. A single unit at a time is transfused when the Hb
### Table 1  Schedule of enrolment, interventions, data collection and outcome assessments

<table>
<thead>
<tr>
<th></th>
<th>Trauma</th>
<th>ICU</th>
<th>Hospital</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enrolment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility screen</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intervention—transfusion strategy</strong></td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liberal (Hb&gt;100 g/L) or restrictive (Hb&gt;70 g/L)</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pre-randomisation data collection</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trauma characteristics</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory results</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Secondary insults</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Cointerventions</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurosurgical and non-neurosurgical interventions</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood product transfusions</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Transfusion reactions</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td><strong>Daily data collection</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory results</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary insults</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Cointerventions</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Neurosurgical and non-neurosurgical interventions</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood product transfusions</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Transfusion complications</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Protocol deviation/violation</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trial outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glasgow Outcome Scale extended</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Mortality</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Functional Independence Measure</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>EuroQoL 5-Dimension 5-Level</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Quality of Life after Brain Injury (QOLIBRI)</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Health Questionnaire-9</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td><strong>Tertiary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red blood cells transfusion</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Lowest Hb</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Length of mechanical ventilation</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Length of stay</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Transfusion complications</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

*Performed retrospectively after randomisation.

Hb, haemoglobin; ICU, intensive care unit.
threshold is reached unless there is an active and uncon-
trolled bleeding requiring urgent care. Additional RBC
transfusions are given if the post-transfusion Hb level
remains below the assigned threshold. In both groups,
RBCs are transfused within 3 hours after the Hb transfu-
sion threshold is reached.

Compliance
Potential protocol deviations and violations are reported
to the Coordinating Centre within 72 hours and further
classified into four categories (figure 2), reflecting the
following situations wherein: (1) an RBC transfusion
occurred while the Hb threshold is not reached, (2)
more than one unit is transfused without reassessing the
Hb level between transfusions, (3) the delay between
reaching the transfusion threshold and transfusion is
greater than 3 hours or a transfusion never occurred
despite reaching the transfusion threshold and (4) no
transfusion occurred in the context of life-sustaining
therapy withdrawal. Using a standard operating proce-
dure, an adjudication committee will determine whether
each reported event represents a protocol violation, a
protocol deviation or neither (see online supplemental
appendix 1).

Cointerventions
No intervention other than the allocated transfusion
threshold is protocolised. Standard therapeutic strategies
according to the Brain Trauma Foundation guidelines
are recommended.10

Outcome measures
Our primary and secondary outcome measures are vali-
dated in patients with TBI and aligned with the Common
Data Elements developed by the National Institute of
Neurological Disorder and Strokes.22 All primary and
secondary outcomes are assessed centrally by trained
research personnel blinded to the intervention to mini-
mise the risk of bias during data collection. We chose a
6-month assessment as it is the most common time frame
used in modern TBI trials and corresponds to the plateau
phase of recovery.23 Tertiary outcomes are assessed at

Figure 1 Flow diagram. GCS, Glasgow Coma Scale; Hb, haemoglobin; ICU, intensive care unit; TBI, traumatic brain injury.
participating sites, using standardised definitions (see online supplemental appendix 2).

Primary outcome
We are using the Glasgow Outcome Scale extended (GOSe) to assess neurological outcome at 6 months. The GOSe scale is reliable, sensitive to change and is the most widely used clinical and patient-oriented outcome in this population. It comprises eight ranking levels from 1 (death, least favourable outcome) to 8 (upper good recovery, most favourable outcome).

Secondary outcomes
We are assessing ICU, hospital and 6-month mortality. At 6 months, we measure the Functional Independence Measure (FIM). The FIM has been used for over three decades in TBI patients to assess their progression during rehabilitation. The scale is sensitive to change and evaluates the amount of assistance required to perform 18 basic daily activities (13 physical and five cognitive components). Each component is scored on a 7-point scale, with higher scores indicating a greater degree of independence. We also evaluate the quality of life using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) (generic scale) and the Quality of Life after Brain Injury (QOLIBRI) (TBI-specific scale) questionnaires. To evaluate depression, we use the self-reported Patient Health Questionnaire (PHQ-9), which includes nine items that assess the frequency of depressive symptoms in the past 2 weeks.

Tertiary outcomes
We are capturing the number of RBC units transfused in the ICU, lowest daily Hb, infections, duration of mechanical ventilation and ICU and hospital length of stay. We are also assessing complications related to transfusion.

Data collection
At enrolment, the study team collects baseline characteristics, prerandomisation cointerventions and episodes of secondary cerebral injury, which are defined as thresholds at which therapeutic intervention is recommended by practice guidelines (see tables 1 and 2). We also collect time from eligibility to randomisation and from randomisation to study intervention implementation. Daily, we collect data on secondary injury episodes and cointerventions. At ICU discharge, we collect the length of stay and the duration of mechanical ventilation. At

Table 2 Secondary cerebral injury definitions

<table>
<thead>
<tr>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoxemia</td>
</tr>
<tr>
<td>Hypoxemia Oxygen saturation&lt;90% for ≥ 5 min on pulse oxymetry</td>
</tr>
<tr>
<td>Hypotension</td>
</tr>
<tr>
<td>Hypotension Systolic blood pressure&lt;90 mm Hg for≥5 min</td>
</tr>
<tr>
<td>Intracranial hypertension</td>
</tr>
<tr>
<td>Intracranial pressure&gt;25 mm Hg for≥5 min</td>
</tr>
<tr>
<td>Brain tissue hypoxia</td>
</tr>
<tr>
<td>Brain tissue oxygen tension(PbtO2)&lt; 15 mm Hg for≥5 min or</td>
</tr>
<tr>
<td>Brain tissue oxygen saturation(SbtO2)&gt; 20% below baseline for≥5 min or</td>
</tr>
<tr>
<td>Brain tissue oxygen saturation(SbtO2)&lt;60% for ≥ 5 min</td>
</tr>
</tbody>
</table>
hospital discharge, we collect non-neurosurgical procedures, infections and transfusion reactions that occurred during the hospital stay as well as the reports of the brain imaging (CT and MRI), length of stay, discharge status and location, documentation of prognostic assessment, justifications provided by clinicians for discontinuing life-sustaining therapies and occurrence of death by neurological criteria.

To limit loss to follow-up, we are gathering complete contact information for patients, their family practitioners and caregivers. Local research coordinators send personalised reminders and confirm upcoming interviews with patients. We use flexible schedules for centralised outcome assessment. We obtain survival status of patients lost to follow-up from public registries or by reaching the primary care team. In our previous multicentre, TBI-Prognosis prospective cohort study, we had no losses to follow-up at 6 months using those strategies.39

Data management
The HEMOTION Coordinating Centre, located at the CHU de Québec-Université Laval Research Centre (Québec City, Québec, Canada), oversees the trial coordination. Source documents are kept at each participating site in locked filing cabinets and offices accessible by the site investigators and their authorised personnel. Coded information is entered in a web-based electronic database and stored at the Ottawa Methods Center at OHRI, which meets Health Canada recommendations and Good Clinical Practice for paper-based and electronic document control system. OHRI personnel has secure access to all trial data, but staff from the Coordinating Centre remain blinded to the intervention allocation.

Sample size
Our sample size was calculated based on the proportion of patients who will experience an unfavourable outcome (GOSe ≤4).24 27 28 Assuming a 40% risk of unfavourable outcome in the control group,27 28 a sample size of 712 patients will allow us to detect an absolute risk reduction of 10% with a power of 80% and a type 1 error of 5%. Our sample size is conservative as it was based on the simple dichotomous cut-off and most used definition of an unfavourable outcome in TBI using the GOSe. Based on simulated data, a sliding dichotomy approach will increase our ability to observe the planned effect size with 95% power. To account for an estimated 2% dropout rate and most used definition of an unfavourable outcome in TBI using the GOSe. Based on simulated data, a sliding dichotomy approach will increase our ability to observe the planned effect size with 95% power. To account for an estimated 2% dropout rate and most used definition of an unfavourable outcome in TBI using the GOSe. Based on simulated data, a sliding dichotomy approach will increase our ability to observe the planned effect size with 95% power. To account for an estimated 2% dropout rate and most used definition of an unfavourable outcome in TBI using the GOSe. Based on simulated data, a sliding dichotomy approach will increase our ability to observe the planned effect size with 95% power.

Data safety and monitoring
We adopted the Data Safety and Monitoring Committee (DSMC) charter template from the DAMOCLES Study Group (see online supplemental appendix 3).45 The DSMC includes an international expert in transfusion medicine, a senior biostatistician and epidemiologist and a neurologist with expertise in neurocritical care. Periodically, the DSMC will independently review reports received...
directly from the Ottawa Methods Centre, including blinded serious adverse events (SAE) reports, protocol adherence, indicators of trial management (eg, enrollment, consent). The DSMC will also blindly evaluate the primary outcome at the interim analysis of 50% enrollment using the Haybittle-Peto criterion (p<0.001). 46 - 49

**Serious adverse events**

Our rationale for reporting SAE is in agreement with a statement on academic trials in critically ill patients. 50 Several potential SAEs are already reported as outcomes, defined *a priori*, while other events are commonly expected ICU events. Potential SAEs not reported as study outcomes or that are not common ICU events will be defined as any postrandomisation adverse occurrence or event that is determined to be directly attributable to the study intervention, that requires inpatient hospitalisation after discharge or prolongation of existing hospitalisation; that results in persistent or significant disability/ incapacity; or that results in a congenital anomaly/birth defect; that is life threatening; that results in death. Any event that ICU physicians or site investigators label as unexpected will be described fully. These will be collated and submitted to the DSMC.

**Data monitoring**

The HEMOTION Coordinating Centre team verifies data entered for completeness and accuracy (eg, range checks for data value), generate queries and communicate with the sites as required. The frequency of the verifications depends on the site enrolment rates, with high enrolling sites having more than one monitoring visit. We are conducting remote continuous monitoring activities, including monitoring visits (remotely or on-site if required), and will perform a final closeout virtual visit for each site.

**Patient and public involvement**

Representatives from Brain Injury Canada, a non-governmental organisation whose vision is to promote a better quality of life for people affected by acquired brain injury, 51 were involved in the trial design and are involved in its conduction. Patient and caregiver engagement ensures that our study objectives are tailored to their needs.

**Trial oversight**

The HEMOTION Steering Committee is comprised of coinvestigators with expertise in TBI and neurocritical care, neurosurgery, haematology, transfusion research, trauma, critical care and large-scale multicentre trials. Knowledge users from various organisations and their representatives are also part of the Steering Committee. These organisations are the *Institut national d’excellence en santé et service sociaux*, Canadian Anesthesiologists Society, Canadian Blood Services and Brain Injury Canada. We have established an Executive Committee to address day-to-day clinical and methodological issues. The Executive Committee is composed of the three principal investigators and is supported by the project manager and trial coordinator. The HEMOTION trial is being conducted under the auspices of the CCCTG, an inclusive group of healthcare professionals that promotes and assists in the implementation of investigator-initiated, patient-oriented, multicentre research in critically ill patients. The trial is also conducted in collaboration with the Canadian Perioperative Anesthesia Clinical Trials Group and the CTRC that was created to enhance collaborations among Canadian scientists working in anesthesia and perioperative medicine, and on different aspects of the continuum of care of patients with TBI, respectively.

**ETHICS AND DISSEMINATION**

**Research ethics approval and consent process**

We obtained approval from the research ethics board prior to the initiation of the trial at each participating centre (see online supplemental appendix 4). Since all patients with TBI are temporarily unable to provide an informed consent, initial consent is sought from a surrogate decision-maker (see Informed Consent Form in online supplemental appendix 5). If a surrogate decision-maker is not available, a deferred informed consent approach is used where authorised by the local research ethics board as the research risk to patients is minimal, and the studied transfusion strategies are part of usual care in many centres 12 - 13 and considered acceptable by clinicians caring for these patients. 16 - 21 A deferred consent approach has been previously used in RBC transfusion strategy trials with no safety issues. 52 - 53 Should the patient regain capacity to consent, the consent to continue participation is sought. If the study intervention is suspended for any reason, we pursue data collection unless consent is denied.

**Protocol amendments**

All past and future changes to the protocol are approved by research ethics committees prior to implementation. Shortly after the ethics approval was obtained and recruitment began, we amended the protocol to detail one exclusion criteria, modify the size of the permuted blocks used for randomisation, specify the number of interim analyses and shorten the time frame to report protocol violations to the Coordinating Centre (online supplemental appendix 6). In the spring of 2022, we implemented additional amendments and increased the sample size to compensate for postrandomisation exclusions, consent withdrawals and losses-to-follow-up observed at the interim analysis. We detailed the adjudication process for protocol deviations and violations, corrected some administrative details (number of participating sites and countries, updated references) and modified the prognostic model to be used in the sliding dichotomy analysis.

**Confidentiality**

Confidentiality is maintained by coded identification, password-protected files and websites, locked filing
cabinets and offices. Direct identifiers are removed and replaced with a code. Site investigators can re-identify specific patients, if required by authorised persons. The code list is kept in secured cabinets and offices at each participating site, only accessible by the site investigators and their authorised personnel. Electronic data are physically and virtually secured in the data centre physically located at OHRI.

Dissemination

The findings from this trial will be shared with relevant brain injury organisations and healthcare professionals, through the publication of manuscripts, conference presentations and seminars. Based on the findings, this trial will engage knowledge translation specialists to build an implementation strategy to reach as many stakeholders and members of the medical community as possible, to help reduce transfusion-related practice variation and thereby promote better outcomes for patients with TBI.

Current trial status

Recruitment began in September 2017 at the CHU de Québec—Université Laval and is currently ongoing at 34 recruiting sites in Canada, the United Kingdom, Brazil and France. The recruitment was initially planned to end in spring 2021. As of March 2022, 75% of the target sample size was achieved. Due to the COVID-19 pandemic and the increase of the sample size, the recruitment is expected to be completed in winter 2023.

Author affiliations

1Population Health and Optimal Practices Research Unit (Trauma — Emergency — Critical Care Medicine), CHU de Québec-Université Laval Research Center, Québec City, Québec, Canada
2Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval, Québec City, Québec, Canada
3Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
4Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
5Centre de Recherche du CHU Sainte-Justine, Montréal, Québec, Canada
6Department of Internal Medicine, Section of Hematology/Oncology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
7CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Manitoba, Canada
8Department of Critical Care, The Ottawa Hospital, Ottawa, Ontario, Canada
9Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK
10Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
11Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
12Center for Clinical Epidemiology & Evaluation, Vancouver General Hospital, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada
13Department of Critical Care Medicine, Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada
14Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada
15Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
16Li Ka Shing Knowledge Institute, Unity Health Toronto-St. Michael’s Hospital, Toronto, Ontario, Canada
17Department of Medicine, Division of Neurology, Queen’s University, Kingston, Ontario, Canada
18Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
19Department of Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada
20Centre de Recherche du CHU de Sherbrooke, Centre Intégrié Universitaire de Santé et de Services Sociaux de l’Estrie—Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada
21Department of Family and Emergency Medicine, Université Laval, Québec City, Québec, Canada
22Department of Surgery, Division of Neurosurgery, Université Laval, Québec City, Québec, Canada
23Department of Anesthesiology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
24Department of Critical Care Medicine, McGill University, Montréal, Québec, Canada
25Departments of Emergency Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
26Department of Critical Care, Dalhousie University, Halifax, Nova Scotia, Canada
27Department of Medicine, Université Laval, Québec City, Québec, Canada
28Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

Twitter Alexis F Turgeon AlexisTurgeon- @HEMOTION_trial @CONT_ULALIAL. Ryan Zarzychanski @RZaryzychanski, Shane English @shane_w_english, Ammariame Docherty @addocherty79, Karen E. A. Bums @KarenBumsk, John Gordon Boyd @jgordonboyd, Ian Ball @Ball, Francois Lamontagne @LamontagneFran, Maude St-Onge @MaudeStOnge, Lynne Moore @Moore, Robert S Green @NSTrauma, Alison Fox-Robichaud @drfoxrob and Francois Lauzier @LauzierFrancoi1

Acknowledgements We want to thank the HEMOTION Trial Team members, the Canadian Critical Care Trials Group, the Canadian Perioperative Anesthesia Clinical Trials Group and the Canadian Traumatic Brain Injury Research Consortium for the ongoing support and collaboration. More importantly, we want to thank patients and their caregivers for their important participation in contributing in the HEMOTION trial.

Contributors AFT, DAF and FLau originally designed the trial and drafted the manuscript. LC, M-PP, RZ, SE, AD, TW, DG, AHK, DS, KEAB, JGB, JCM, DJK, IB, PCH, FLam, OC, MS-O, PLB, LM, XN, AR, KK, RSG, VL and AF-R contributed to the protocol and revised the manuscript for important intellectual content. All authors approved the final version of the manuscript.

Funding The HEMOTION trial is funded by peer-reviewed grants from the Canadian Institutes of Health Research (CIHR) (#149334 and #148443). The CIHR have no role in the design of the trial, its conduct, the interpretation of data and the dissemination of the trial results. AFT is the Chairholder of the Canadian Research Chair in Critical Care Neurology and Trauma, Flau, LM, MS-O and Flam are recipients of salary support Awards from the Fonds de la Recherche du Québec-Santé (FRQS). RZ is the Chairholder of the Lyonel G Israel Research Chair in Hematology.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Consent obtained from next of kin.

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content

includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**
Alexis F Turgeon http://orcid.org/0000-0001-5675-8791
Dean A Ferguson http://orcid.org/0000-0002-3389-2485
Alison Fox-Robichaud http://orcid.org/0000-0001-9912-3606
Francois Lauzier http://orcid.org/0000-0002-6530-5513

**REFERENCES**